HSD17B10 and cancer: These inhibitors were characterized further througha series of assays demonstrating ligand–protein interactionsand co-crystallography, revealing un-/non-competitive inhibition withrespect to the cofactor NADH, unlike previously published inhibitors.This work significantly advances the development of 17β-HSD10-targetingtherapeutics, offering new potential leads for treating Alzheimer’sdisease and cancers.